WO2003039450A2 - Improvements in or relating to inhibition of viruses - Google Patents

Improvements in or relating to inhibition of viruses Download PDF

Info

Publication number
WO2003039450A2
WO2003039450A2 PCT/GB2002/005031 GB0205031W WO03039450A2 WO 2003039450 A2 WO2003039450 A2 WO 2003039450A2 GB 0205031 W GB0205031 W GB 0205031W WO 03039450 A2 WO03039450 A2 WO 03039450A2
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
analogue
virus
composition according
ribonucleoside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2002/005031
Other languages
English (en)
French (fr)
Other versions
WO2003039450A3 (en
Inventor
David Loakes
Daniel Brown
Jan Balzarini
Kei Moriyama
Kazuo Negishi
Craig Cameron
Jamie Arnold
Christian Castro
Victoria Korneeva
Jason Graci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0126701A external-priority patent/GB0126701D0/en
Application filed by Medical Research Council filed Critical Medical Research Council
Priority to JP2003541742A priority Critical patent/JP2005507944A/ja
Priority to AU2002337388A priority patent/AU2002337388A1/en
Priority to EP02772630A priority patent/EP1441744A2/en
Publication of WO2003039450A2 publication Critical patent/WO2003039450A2/en
Publication of WO2003039450A3 publication Critical patent/WO2003039450A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Definitions

  • RNA virus is considered to include all viruses with an RNA genome (encompassing both “conventional” RNA viruses and retroviruses) and any virus which requires a genomic RNA intermediate for the purposes of replication.
  • relevant viruses include ortho- and paramyxo viruses, polio virus, rhinovirus, retroviruses (especially HIV-1 and HIV-2), hepatitis B and C viruses (HBV and HCV respectively), rotaviruses, flaviviruses (e.g. West Nile virus) and certain arboviruses (e.g. Dengue Fever virus).
  • Physiologically acceptable excipients, diluents and carriers are well known to those skilled in the art of medical formulations and include, for example: saline, Ringer's solution, distilled water, dextrose solution, calcium carbonate, silicates, starches and modified starches and plant-derived polysaccharide gums and gels (e.g. xanthan gum; carrageenans and the like).
  • Figure 23 is a schematic representation of a transcription system of use in screening ribonucleoside analogues for use in the present invention.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/GB2002/005031 2001-11-07 2002-11-07 Improvements in or relating to inhibition of viruses Ceased WO2003039450A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2003541742A JP2005507944A (ja) 2001-11-07 2002-11-07 ウイルスの抑制における改善およびその関連
AU2002337388A AU2002337388A1 (en) 2001-11-07 2002-11-07 Improvements in or relating to inhibition of viruses
EP02772630A EP1441744A2 (en) 2001-11-07 2002-11-07 Improvements in or relating to inhibition of viruses

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0126701A GB0126701D0 (en) 2001-11-07 2001-11-07 Improvements in or relating to induction of mutations in viruses
GB0126701.2 2001-11-07
US10/207,005 2002-07-30
US10/207,005 US7049303B2 (en) 2001-11-07 2002-07-30 Inhibition of viruses

Publications (2)

Publication Number Publication Date
WO2003039450A2 true WO2003039450A2 (en) 2003-05-15
WO2003039450A3 WO2003039450A3 (en) 2003-08-21

Family

ID=26246745

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/005031 Ceased WO2003039450A2 (en) 2001-11-07 2002-11-07 Improvements in or relating to inhibition of viruses

Country Status (5)

Country Link
US (2) US7049303B2 (cg-RX-API-DMAC10.html)
EP (1) EP1441744A2 (cg-RX-API-DMAC10.html)
JP (1) JP2005507944A (cg-RX-API-DMAC10.html)
AU (1) AU2002337388A1 (cg-RX-API-DMAC10.html)
WO (1) WO2003039450A2 (cg-RX-API-DMAC10.html)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009129120A2 (en) 2008-04-15 2009-10-22 Rfs Pharma, Llc Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
EP1572097A4 (en) * 2002-09-30 2010-02-17 Smithkline Beecham Corp NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF INFECTIONS WITH THE HEPATITIS C-VIRUS
US8420816B2 (en) 2009-06-08 2013-04-16 Takeda Pharmaceutical Company Limited Dihydropyrrolonaphthyridinone compounds as inhibitors of JAK
US8735599B2 (en) 2004-06-18 2014-05-27 Novartis Vaccines And Diagnostics, Inc. Substituted imidazole derivates
US8802840B2 (en) 2005-03-08 2014-08-12 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
WO2023152709A1 (en) * 2022-02-14 2023-08-17 Arbutus Biopharma Corporation Rna polymerase inhibitors and methods using same

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094768B2 (en) * 2002-09-30 2006-08-22 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis C virus infection
US7169918B2 (en) * 2003-10-27 2007-01-30 Genelabs Technologies, Inc. Methods for preparing 7-(2′-substituted-β-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives
US9809616B2 (en) 2012-10-29 2017-11-07 Emory University Pyrimidine nucleosides and their monophosphate prodrugs for the treatment of viral infections and cancer
WO2016106050A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
RU2020116571A (ru) 2017-12-07 2021-11-22 Эмори Юниверсити N4-гидроксицитидин и производные и связанные с этим противовирусные применения

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8802687D0 (sv) 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
WO1990006319A1 (en) 1988-12-05 1990-06-14 Schering Corporation Antiviral dimers and trimers
DK62592D0 (cg-RX-API-DMAC10.html) * 1992-05-14 1992-05-14 Novo Nordisk As
US5773424A (en) 1994-12-16 1998-06-30 Research Corporation Technologies, Inc. Treatment of toxoplasmosis
ES2276404T3 (es) 1995-06-07 2007-06-16 Emory University Nucleosidos con actividad antivirus de la hepatitis-b.
AU727177B2 (en) 1996-10-16 2000-12-07 Icn Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses thereof
NZ507848A (en) * 1996-10-28 2005-01-28 Univ Washington Method of increasing the mutation rate of a virus in a non-human by administering an RNA nucleoside analogue to a virally infected cell
EA200700564A1 (ru) 1998-02-25 2007-08-31 Эмори Юниверсити 2`-фторнуклеозиды
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
JP2003524636A (ja) 1999-12-22 2003-08-19 インスパイアー ファーマシューティカルズ，インコーポレイティド プリン性受容体アゴニストによる胃腸管の処置方法

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1572097A4 (en) * 2002-09-30 2010-02-17 Smithkline Beecham Corp NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF INFECTIONS WITH THE HEPATITIS C-VIRUS
US8735599B2 (en) 2004-06-18 2014-05-27 Novartis Vaccines And Diagnostics, Inc. Substituted imidazole derivates
US8802840B2 (en) 2005-03-08 2014-08-12 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
WO2009129120A2 (en) 2008-04-15 2009-10-22 Rfs Pharma, Llc Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
EP2268288A4 (en) * 2008-04-15 2012-05-30 Rfs Pharma Llc NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF CALICIVIRIDAE INFECTIONS, INCLUDING NOROVIRUS INFECTIONS
US8415321B2 (en) 2008-04-15 2013-04-09 Raymond F. Schinazi Nucleoside derivatives for treatment of Caliciviridae infections, including Norovirus infections
US8420816B2 (en) 2009-06-08 2013-04-16 Takeda Pharmaceutical Company Limited Dihydropyrrolonaphthyridinone compounds as inhibitors of JAK
US8785429B2 (en) 2009-06-08 2014-07-22 Takeda Pharmaceutical Company Limited Dihydropyrrolonaphthyridinone compounds as inhibitors of JAK
WO2023152709A1 (en) * 2022-02-14 2023-08-17 Arbutus Biopharma Corporation Rna polymerase inhibitors and methods using same

Also Published As

Publication number Publication date
WO2003039450A3 (en) 2003-08-21
US7049303B2 (en) 2006-05-23
US20030130226A1 (en) 2003-07-10
AU2002337388A1 (en) 2003-05-19
US20050043268A1 (en) 2005-02-24
EP1441744A2 (en) 2004-08-04
JP2005507944A (ja) 2005-03-24

Similar Documents

Publication Publication Date Title
EP1284741B1 (en) 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of viral infections
Graci et al. Quasispecies, error catastrophe, and the antiviral activity of ribavirin
Chen et al. The search for nucleoside/nucleotide analog inhibitors of dengue virus
Bryant et al. Antiviral L-nucleosides specific for hepatitis B virus infection
EP2848624B1 (en) 2',4'-substituted nucleosides as antiviral agents
Martinez-Montero et al. Rigid 2′, 4′-difluororibonucleosides: synthesis, conformational analysis, and incorporation into nascent RNA by HCV polymerase
US4963662A (en) Fluorinated nucleosides and method for treating retrovirus infections therewith
Meier et al. cyclo Sal-Pronucleotides of 2 ‘-Fluoro-ara-and 2 ‘-Fluoro-ribo-2 ‘, 3 ‘-dideoxyadenosine as a Strategy to Bypass a Metabolic Blockade
KR101201552B1 (ko) 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
JPWO2002051425A1 (ja) Ｃ型肝炎治療剤
WO2018009652A1 (en) Compounds, compositions, and methods for the treatment of disease
US20050043268A1 (en) Inhibition of viruses
Graci et al. Lethal mutagenesis of poliovirus mediated by a mutagenic pyrimidine analogue
Harrington et al. 3'-azido-3'-deoxythymidine (AZT) monophosphate: an inhibitor of exonucleolytic repair of AZT-terminated DNA
Jonsson et al. Potential importance of error catastrophe to the development of antiviral strategies for hantaviruses
WO2021155119A2 (en) Therapeutics for covid-19
Yang et al. Highly selective action of triphosphate metabolite of 4′-ethynyl D4T: a novel anti-HIV compound against HIV-1 RT
Benzaria et al. 2′-C-Methyl branched pyrimidine ribonucleoside analogues: potent inhibitors of RNA virus replication
Abramova et al. Synthesis of morpholine nucleoside triphosphates
Jashes et al. Inhibitory effects of EICAR on infectious pancreatic necrosis virus replication
Cheng et al. DNA polymerases versus HIV reverse transcriptase in AIDS therapy
JP4986617B2 (ja) ヘテロアリール化合物のプロドラッグ
US5153180A (en) Fluorinated nucleosides and process for treating retrovirus infections therewith
Ohrui Development of modified nucleosides that have supremely high anti-HIV activity and low toxicity and prevent the emergence of resistant HIV mutants
Alaoui et al. Inhibition of hepatitis B virus replication by nucleoside enantiomers of β-2′, 3′-dideoxypurine analogues

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003541742

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002772630

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002772630

Country of ref document: EP